Everything you need to know about the first dual GIP/GLP-1 receptor agonist for metabolic research
Tirzepatide is a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Approved by the FDA under the brand name Mounjaro, it represents a breakthrough in metabolic research as the first dual-incretin therapy.
The molecule is a 39-amino acid modified peptide with a C20 fatty diacid moiety that enables once-weekly dosing. Its dual mechanism targets both GIP and GLP-1 receptors, providing enhanced metabolic benefits.
Enhances insulin sensitivity, promotes nutrient storage, and may have direct effects on fat tissue metabolism.
Stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety.
Significant body weight reduction in clinical trials, averaging 20%+ of initial body weight.
Superior glycemic control with average HbA1c reductions of 2.0-2.5%.
Positive effects on cardiovascular risk markers including blood pressure and lipids.
Research Use Only: This product is intended exclusively for laboratory research purposes. Not for human consumption. All research must be conducted in controlled laboratory settings by qualified personnel in accordance with applicable laws and regulations.
